CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » BLOGS

ONCOLOGY. Vol. 26 No. 9
MOBILE HEALTH UPDATE 

Is Diagnosing Cancer With a Smartphone in Our Future?

By Satish Misra, MD1 | June 1, 2012
1Managing Editor at iMedicalApps

From the flow cytometers and PET scanners that confirm a cancer diagnosis to the proton therapy cyclotrons and bioengineered chemotherapy agents that deliver the treatment, oncology is a field driven by cutting edge technology. The proposition, then, that a consumer smartphone could somehow become part of the diagnostic toolkit of an oncologist may seem ridiculous. There are, however, many researchers and start-ups that would disagree.

The $200 micro-NMR Device

Satish Misra, MD, Managing Editor, iMedicalApps

Dr. Ralph Weissleder and a team of researchers at Harvard Medical School described a micro-NMR device last year in the Science Translational Magazine that pairs with a smartphone to analyze biologic samples. Designed as a low-cost, point-of-care device, the device uses magnetic nanoparticles targeted to markers of interest to analyze a sample for a cell population of interest. The device is currently undergoing trials for, among other things, detection of malignant cells in peripheral blood. Its not hard to imagine the potential implications of this device. With the right markers, one could potentially diagnose renal and bladder cancers from urine samples, hematologic malignancies from peripheral blood, or oropharyngeal malignancies from saliva - regardless of whether the patient is at the Mayo Clinic or in the Saharan desert. It could also offer an alternative, particularly in resource poor settings, where biopsies may be feasible but traditional analytic tools are unavailable.

A camera attachment that does more than post to Twitter

Coming off a series of awards is Dr. Manu Prakash of Stanford's Biological Engineering Department and his lab's OScan device. This device uses fluorescent imaging, using a simple attachment to a camera phone device, to analyze visible soft tissue in the oropharynx and assess for malignant tissue. Enabling the detection of oral malignancies, a particular problem in many resource-poor areas, this device could enable far earlier detection and, as a result, earlier intervention. With OScan, the image is generated, analyzed, and then transmitted wirelessly to a remote physician for further management. As many resource poor settings are nevertheless rich in wireless coverage, this device has a lot of potential. Application of this technology with, for example, eyeNETRA's $2 smartphone attachment for vision assessment could even further broaden the reach and impact.

Using smartphones to key an eye on skin lesions

For most cutaneous malignancies, the key to effective therapy is early diagnosis. However, appropriately evaluating and tracking concerning lesions isn't always easy. The mobile dermascope, from Cellscope or Handyscope, may soon change that. A simple, low-cost attachment for smartphones using their native cameras, the dermascope can not only capture high resolution images but can also wirelessly transmit the images to a dermatologist for screening. While teledermatology does have its tradeoffs, its not hard to imagine how this device could be valuable in tracking suspicious lesions, particularly in under-served areas. Add on software that can analyze the image and predict a malignancy risk, this tool could become quite powerful.

Sniffing out malignancy in the "lab"

The lab-on-a-chip concept is gaining popularity, with even NASA jumping into the mix with a peripheral to "sniff" out disease. Other groups are using similar peripherals to diagnose disease from biologic samples, such as one that uses urine to diagnose ovarian cancer on a smartphone. The potential applications are broad, limited only by the ability of researchers to find sensitive and specific markers of disease.

Thanks to the race between smartphone manufacturers to pack ever more processing power and functionality into their devices, the smartphone is a natural platform on which to build a wide range of tools. These devices, however, are all in their earliest phases of application, meaning that there is a long way to go before they find their place in the diagnostic toolkit of a practicing oncologist. But the day when oncologists reach for their smartphone to diagnose cancer is probably not all that far off.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 

 
MORE BLOGS

50 Shades of Pink—And Why It Helps to Know the Difference
May 17, 2013
I Can’t Talk to You With a Gun in My Face
May 3, 2013
“This Is My Last Day on Earth”
May 2, 2013
Conflicts of Interest in Medicine: What About Ties to Payers?
April 5, 2013
“How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
March 26, 2013


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy